Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First multi-centre, randomized, vehicle-controlled, double-blind, parallel group pivotal phase 3 trial of an ultra-potent topical corticosteroid product being developed for the treatment of plaque psoriasis using the Company's patented Multiplexed Molecular Penetration Enhancer ("MMPE™") technology

Trial Profile

First multi-centre, randomized, vehicle-controlled, double-blind, parallel group pivotal phase 3 trial of an ultra-potent topical corticosteroid product being developed for the treatment of plaque psoriasis using the Company's patented Multiplexed Molecular Penetration Enhancer ("MMPE™") technology

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Feb 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CTX 101 (Primary)
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Sponsors Crescita Therapeutics

Most Recent Events

  • 18 Feb 2020 New trial record
  • 11 Feb 2020 Results presented in a Crescita Therapeutics Media Release.
  • 11 Feb 2020 According to a Crescita Therapeutics media release, primary end point ( Investigator's Global Assessment (IGA's) treatment success at the end of study, has been met.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top